Incyte HCP Unsubscribe

OPT OUT

We are sorry you no longer wish to receive communication.

Fields marked with an asterisk (*) are required fields.

Email *

Unsubscribe from marketing communications related to:

Therapeutic Area(s) & Therapies

Oncology

Jakafi® (ruxolitinib) MONJUVI® (tafasitamab-cxix) Niktimvo™ (axatilimab-csfr) PEMAZYRE® (pemigatinib) ZYNYZ® (retifanlimab-dlwr)

Dermatology

OPZELURA® (ruxolitinib)

Unsubscribe from all email communications from Incyte Corporation:

All Incyte Corporation, including disease educational materials, brand-related content, sales communications, Incyte corporate materials, etc.

Jakafi, MONJUVI, PEMAZYRE, ZYNYZ, and OPZELURA are registered trademarks of Incyte.
Niktimvo is a trademark of Incyte.
Incyte and the Incyte logo are registered trademarks of Incyte.
© 2024, Incyte. MAT-INC-02599 12/24